WARBY PARKER CL.A -,0001 Aktie Logo
US93403J1060
A3C49J
WRBY

WARBY PARKER CL.A -,0001 Aktie

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 26,37 € (+22,20 %). La mediana es de 25,85 € (+19,79 %).

Comprar
  9
Mantener
  7
Vender
  0

  • Blacksheep launches in US with prescription glasses from $3.98, targets Warby Parker and Luxottica

    Blacksheep, led by CEO Pierre Wizman, is entering the U.S. market offering prescription glasses starting at $3.98 and selling designer frames for $1 with low-cost lenses, claiming on-demand production and minimal margins by cutting out middlemen. Wizman accuses incumbents of massive markups and vows to disrupt Luxottica’s dominance and Warby Parker’s pricing, while Warby Parker defends its value-driven, feature-rich products. Industry peers express skepticism about the feasibility and quality of such low-priced eyewear and note manufacturing and material costs as key differentiators. » Más en forbes.com


  • Warby Parker: shareholders elect directors, ratify Ernst & Young and approve compensation

    At the annual meeting shareholders elected Dave Gilboa, Youngme Moon and Ronald Williams to the board (term to 2029), ratified Ernst & Young LLP as independent auditors for 2026 and approved, in a non-binding advisory vote, the compensation of the named executive officers. About 95.97% of the voting power was represented. Warby Parker also reported Q1 results with EPS of $0.03 (below expectations) and revenue of $242.45 million (slightly above expectations), and announced an "Intelligent Eyewear" collaboration with Google and Samsung. » Más en de.investing.com


  • Warby Parker misses earnings forecast, revenue slightly above expectations

    Warby Parker reported Q1 2026 EPS of $0.03 versus $0.15 expected, while revenue of $242.45 million topped expectations of $239.82 million by 1.1%. Retail sales grew 13.6% year‑over‑year, while e‑commerce declined after the discontinuation of the Home-Try-On program. Adjusted gross margin and profitability are under pressure; adjusted EBITDA was $29.6 million (margin 12.2%). The company reaffirmed its full-year revenue guidance of $959–976 million and plans to invest in the planned launch of AI glasses in partnership with Google and Samsung. » Más en de.investing.com

En 2022, WARBY PARKER CL.A -,0001 Aktie ya ha pagado 7,07 € en dividendos. El último pago fue en abril 2022.

Datos financieros de la empresa

En el último trimestre, WARBY PARKER CL.A -,0001 Aktie tuvo unos ingresos de 206,36 M € y un beneficio neto de 4,07 M €
(EUR) jun 2026
YoY
Ingresos 206,36 M 13,40 %
Beneficio bruto 119,56 M 24,05 %
Beneficio neto 4,07 M 373,75 %
EBITDA 30,8 M 265,05 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
2643,74 M €
Número de acciones
122,72 M
Máximo/mínimo de 52 semanas
26,71 € - 12,89 €
Dividendos No
Beta
1,93
Ratio P/E
379,94
Ratio PEG
0,10
Ratio P/B
7,90
Ratio P/S
3,37

Perfil de la empresa

Warby Parker Inc. stellt Brillenprodukte her. Das Unternehmen bietet Brillen, Sonnenbrillen, lichtempfindliche Linsen, Blaulichtfilter-Linsen und Kontaktlinsen sowie Zubehör wie Etuis, Linsen-Kits mit Anti-Beschlag-Spray, Etuis und Anti-Beschlag-Linsenspray. Das Unternehmen bietet über seine Einzelhandelsgeschäfte, seine Website und seine mobilen Apps auch Augenuntersuchungen und Sehtests direkt für Verbraucher an. Am 16. Mai 2022 hatte das Unternehmen 160 Einzelhandelsgeschäfte in den Vereinigten Staaten und Kanada. Das Unternehmen war früher als JAND, Inc. bekannt und änderte im Juni 2021 seinen Namen in Warby Parker Inc. um. Warby Parker Inc. wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in New York, New York.

Nombre
WARBY PARKER CL.A -,0001 Aktie
CEO
Neil Harris Blumenthal
Sede New York City, ny
Estados Unidos
Sitio web
Sector
Salud
Industria
Equipos y suministros sanitarios
Salida a bolsa
29/09/2021
Empleados 4036

Símbolos bursátiles

Bolsa Símbolo
NYSE
WRBY

Descubrir activos

Los accionistas de WARBY PARKER CL.A -,0001 Aktie también invierten en los siguientes activos

🍪

Parqet  usa cookies. Más información